A patient taking inavolisib 9 mg once daily with palbociclib and fulvestrant develops a fasting glucose of 15.4 mmol/L, without ketoacidosis.

Question

A patient taking inavolisib 9 mg once daily with palbociclib and fulvestrant develops a fasting glucose of 15.4 mmol/L, without ketoacidosis. Inavolisib is interrupted and antihyperglycaemic treatment is intensified. The fasting glucose falls to 8.4 mmol/L on day 6. What is the SmPC-concordant inavolisib action?

Accepted Answer

Resume inavolisib at 9 mg once daily after recovery to 8.9 mmol/L by day 6

Answer

Resume inavolisib at 6 mg once daily after recovery to 8.9 mmol/L by day 6

Answer

Resume inavolisib at 3 mg once daily after recovery to 8.9 mmol/L by day 6

Answer

Permanently discontinue inavolisib after the first fasting-glucose excursion above 13.9 mmol/L

Answer

Resume inavolisib at 6 mg once daily after recovery to 11.1 mmol/L by day 6

Melanoma Transplant — SCE Medical Oncology MCQ